$KACLF
Kairous Acquisition Corp. Ltd Stock $kaclf

$kaclf Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224020672 Filed on May 20, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin			$213.8K
YoY Change			204.79%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$158.3K	$213.8K
YoY Change		-25.95%	204.78%
Operating Profit		-$158.3K	-$213.8K
YoY Change		-25.95%	204.79%
Interest Expense			$230.9K
YoY Change			2815.53%
% of Operating Profit
Other Income/Expense, Net		$204.8K	$230.9K
YoY Change		-11.29%	2815.53%
Pretax Income			$17.13K
YoY Change			-127.53%
Income Tax
% Of Pretax Income
Net Earnings		$46.54K	$17.13K
YoY Change		171.65%	-127.54%
Net Earnings / Revenue
Basic Earnings Per Share		$0.01	$0.00
Diluted Earnings Per Share		$0.01	$0.00
COMMON SHARES
Basic Shares Outstanding	3.684M shares	3.684M shares	4.436M shares
Diluted Shares Outstanding		3.684M shares	4.436M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$990.00	$390.00	$123.3K
YoY Change	-97.53%	-99.68%	-76.95%
Cash & Equivalents	$985.00	$385.00	$123.3K
Short-Term Investments
Other Short-Term Assets	$72.20K	$16.72K	$153.7K
YoY Change	3.14%	-89.12%	21.97%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$73.19K	$17.11K	$277.0K
YoY Change	-34.75%	-93.82%	-58.09%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$16.15M	$15.79M	$22.41M
YoY Change	-29.16%	-29.54%	-71.55%
Other Assets			$0.00
YoY Change			-100.0%
Total Long-Term Assets	$16.15M	$15.79M	$22.41M
YoY Change	-29.16%	-29.54%	-71.56%
TOTAL ASSETS
Total Short-Term Assets	$73.19K	$17.11K	$277.0K
Total Long-Term Assets	$16.15M	$15.79M	$22.41M
Total Assets	$16.23M	$15.81M	$22.69M
YoY Change	-29.19%	-30.33%	-71.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$307.7K	$309.7K	$218.8K
YoY Change	156.38%	41.56%	3025.29%
Accrued Expenses			$15.00K
YoY Change			0.0%
Deferred Revenue
YoY Change
Short-Term Debt	$2.901M	$2.521M	$1.090M
YoY Change	130.27%	131.29%	1457.14%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.209M	$2.831M	$1.324M
YoY Change	131.93%	113.84%	1338.88%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.730M	$2.730M	$2.730M
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Liabilities	$2.730M	$2.730M	$2.730M
YoY Change	0.0%	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.209M	$2.831M	$1.324M
Total Long-Term Liabilities	$2.730M	$2.730M	$2.730M
Total Liabilities	$5.939M	$5.561M	$4.054M
YoY Change	44.37%	37.17%	43.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$5.866M	-$5.544M	-$3.777M
YoY Change	46.59%	46.78%
Common Stock	$235.00	$235.00	$235.00
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.866M	-$5.544M	-$3.777M
YoY Change
Total Liabilities & Shareholders Equity	$16.23M	$15.81M	$22.69M
YoY Change	-29.19%	-30.33%	-71.45%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income		$46.54K	$17.13K
YoY Change		171.65%	-127.54%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$229.7K	-$94.49K	-$308.0K
YoY Change	91.42%	-69.32%	10.53%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$150.0K	-$150.0K	-$360.0K
YoY Change	25.0%	-58.33%
Cash From Investing Activities	-$150.0K	-$150.0K	-$360.0K
YoY Change	25.0%	-58.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	380.3K	243.1K	660.0K
YoY Change	153.54%	-63.17%
NET CHANGE
Cash From Operating Activities	-229.7K	-94.49K	-308.0K
Cash From Investing Activities	-150.0K	-150.0K	-360.0K
Cash From Financing Activities	380.3K	243.1K	660.0K
Net Change In Cash	610.0	-1.430K	-7.950K
YoY Change	-100.68%	-82.01%	-97.15%
FREE CASH FLOW
Cash From Operating Activities	-$229.7K	-$94.49K	-$308.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Interest Income Other InterestIncomeOther		usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
CY2024Q1	KACL	Management Fees Expense ManagementFeesExpense		usd
CY2023Q1	us-gaap	Management Fee Expense ManagementFeeExpense		usd
	us-gaap	Management Fee Expense ManagementFeeExpense		usd
CY2023Q2	us-gaap	Management Fee Payable ManagementFeePayable		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
	dei	City Area Code CityAreaCode	+662
	dei	Local Phone Number LocalPhoneNumber	255-6851340
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	true
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3683906	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	385	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39359	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16724	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	72810	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	17109	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	112169	usd
CY2024Q1	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	15792577	usd
CY2023Q2	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	22802239	usd
CY2024Q1	us-gaap	Assets Assets	15809686	usd
CY2023Q2	us-gaap	Assets Assets	22914408	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	309689	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	123638	usd
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	1640000	usd
CY2023Q2	us-gaap	Loans Payable Current LoansPayableCurrent	840000	usd
CY2024Q1	KACL	Working Capital Loans Sponsor WorkingCapitalLoansSponsor	881066	usd
CY2023Q2	KACL	Working Capital Loans Sponsor WorkingCapitalLoansSponsor	420000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2830755	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1383638	usd
CY2024Q1	KACL	Deferred Underwriting Commission Non Current DeferredUnderwritingCommissionNonCurrent	2730000	usd
CY2023Q2	KACL	Deferred Underwriting Commission Non Current DeferredUnderwritingCommissionNonCurrent	2730000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	5560755	usd
CY2023Q2	us-gaap	Liabilities Liabilities	4113638	usd
CY2024Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	1337763	shares
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	15792577	usd
CY2023Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	22802239	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2346143	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2346143	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2346143	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2346143	shares
CY2024Q1	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	1337763	shares
CY2023Q2	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	2089816	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	235	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	235	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5543881	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4001704	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-5543646	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-4001469	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15809686	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22914408	usd
	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	45000	usd
	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	44969	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	143295	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	198807	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	697178	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	779006	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	158295	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	213776	usd
	us-gaap	Operating Expenses OperatingExpenses	742178	usd
	us-gaap	Operating Expenses OperatingExpenses	823975	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-158295	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-213776	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-742178	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-823975	usd
	us-gaap	Interest Income Other InterestIncomeOther	1	usd
	us-gaap	Interest Income Other InterestIncomeOther	23	usd
CY2024Q1	us-gaap	Investment Income Net InvestmentIncomeNet	204839	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	230906	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	812040	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	1112564	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	204839	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	230910	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	812041	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1112587	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	46544	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	17134	usd
	us-gaap	Net Income Loss NetIncomeLoss	69863	usd
	us-gaap	Net Income Loss NetIncomeLoss	288612	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3683906	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3683906	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4435959	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4435959	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4140607	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4140607	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7687013	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7687013	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-4001469	usd
CY2023Q3	KACL	Temporary Equity Remeasurement To Redemption Value Adjustment TemporaryEquityRemeasurementToRedemptionValueAdjustment	-659668	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-57815	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-4718952	usd
CY2023Q4	KACL	Temporary Equity Remeasurement To Redemption Value Adjustment TemporaryEquityRemeasurementToRedemptionValueAdjustment	-597533	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	81134	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-5235351	usd
CY2024Q1	KACL	Temporary Equity Remeasurement To Redemption Value Adjustment TemporaryEquityRemeasurementToRedemptionValueAdjustment	-354839	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	46544	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-5543646	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-2232806	usd
CY2022Q3	KACL	Temporary Equity Remeasurement To Redemption Value Adjustment TemporaryEquityRemeasurementToRedemptionValueAdjustment	-355581	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	159284	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2429103	usd
CY2022Q4	KACL	Temporary Equity Remeasurement To Redemption Value Adjustment TemporaryEquityRemeasurementToRedemptionValueAdjustment	-866077	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	112194	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3202986	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3202986	usd
CY2023Q1	KACL	Temporary Equity Remeasurement To Redemption Value Adjustment TemporaryEquityRemeasurementToRedemptionValueAdjustment	-590906	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	17134	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	17134	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3776758	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3776758	usd
	us-gaap	Net Income Loss NetIncomeLoss	69863	usd
	us-gaap	Net Income Loss NetIncomeLoss	288612	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	812040	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	1112564	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-56086	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	43573	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-25363	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	186051	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	182524	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-500040	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-659638	usd
	KACL	Cash Deposited Into Trust Account CashDepositedIntoTrustAccount	800000	usd
	KACL	Cash Deposited Into Trust Account CashDepositedIntoTrustAccount	720000	usd
	KACL	Cash Withdrawn From Trust Account In Connection With Redemption CashWithdrawnFromTrustAccountInConnectionWithRedemption	8621702	usd
	KACL	Cash Withdrawn From Trust Account In Connection With Redemption CashWithdrawnFromTrustAccountInConnectionWithRedemption	58312401	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7821702	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	57592401	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	8621702	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	58312401	usd
	us-gaap	Proceeds From Issuance Of Unsecured Debt ProceedsFromIssuanceOfUnsecuredDebt	800000	usd
	us-gaap	Proceeds From Issuance Of Unsecured Debt ProceedsFromIssuanceOfUnsecuredDebt	720000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	461066	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	300000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7360636	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-57292401	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-38974	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-359638	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39359	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	482965	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	385	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	123327	usd
	KACL	Current Period Remeasurement Adjustment Of Ordinary Shares To Redemption Value CurrentPeriodRemeasurementAdjustmentOfOrdinarySharesToRedemptionValue	1612040	usd
	KACL	Current Period Remeasurement Adjustment Of Ordinary Shares To Redemption Value CurrentPeriodRemeasurementAdjustmentOfOrdinarySharesToRedemptionValue	1832564	usd
CY2021Q4	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	4843252	usd
CY2021Q4	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	1559900	usd
CY2021Q4	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	2730000	usd
CY2021Q4	KACL	Other Offering Costs OtherOfferingCosts	553352	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2730000	usd
	KACL	Condition For Future Business Combination Use Of Proceeds Percentage ConditionForFutureBusinessCombinationUseOfProceedsPercentage	0.80	pure
	KACL	Condition For Future Business Combination Threshold Percentage Ownership ConditionForFutureBusinessCombinationThresholdPercentageOwnership	0.50	pure
	KACL	Threshold Percentage Of Public Shares Subject To Redemption Without Companys Prior Written Consent ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent	0.15	pure
	KACL	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
	KACL	Redemption Period Upon Closure RedemptionPeriodUponClosure	P12M
	KACL	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
	KACL	Maximum Net Interest To Pay Dissolution Expenses MaximumNetInterestToPayDissolutionExpenses	50000	usd
CY2023Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	50000	usd
CY2024Q1	KACL	Working Capital Deficit WorkingCapitalDeficit	2813646	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	385	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zZjZj7j9hJve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zOrX3kkfBRib">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	385	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39359	usd
CY2023Q2	us-gaap	Assets Held In Trust AssetsHeldInTrust	22800000	usd
CY2024Q1	KACL	Cash Held In Trust Account CashHeldInTrustAccount	15800000	usd
	KACL	Offering Costs Associated With Initial Public Offering OfferingCostsAssociatedWithInitialPublicOffering	<p id="xdx_84D_ecustom--OfferingCostsAssociatedWithInitialPublicOffering_zS15w7Wn5Wp2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zksh2i1cA6Y">Offering Costs associated with the Initial Public Offering</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the requirements of the Financial Accounting Standards Board (“FASB”) ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A, <i>“Expenses of Offering.”</i> Offering costs of $<span id="xdx_906_eus-gaap--OperatingCostsAndExpenses_c20230701__20240331_zGttekxOEw2i" title="Transaction costs">894,582</span> consisted principally of costs incurred in connection with preparation for the Initial Public Offering. These offering costs, together with the underwriter fees of $<span id="xdx_902_ecustom--UnderwriterFee_c20230701__20240331_zGlB6yLy7tKa" title="Underwriter fees">4,289,900</span> (or $<span id="xdx_909_eus-gaap--PaymentsForUnderwritingExpense_c20230701__20240331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRakZn3Jn6X1" title="Underwriting fees">1,559,900</span> paid in cash upon the closing of the Initial Public Offering and a deferred fee of $<span id="xdx_906_eus-gaap--OtherUnderwritingExpense_c20230701__20240331__us-gaap--SubsidiarySaleOfStockAxis__custom--DeferredUnderwritingCommissionsMember_zFsCC7UNF8Hi" title="Deferred underwriter fees">2,730,000</span>), were charged to stockholders’ equity upon completion of the Initial Public Offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	894582	usd
	KACL	Underwriter Fee UnderwriterFee	4289900	usd
CY2024Q1	KACL	Working Capital Loans Sponsor WorkingCapitalLoansSponsor	881066	usd
CY2024Q1	KACL	Extension Loans ExtensionLoans	1640000	usd
CY2023	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	5710184	shares
CY2023	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	58312401	usd
CY2024Q1	KACL	Temporary Equity Subject To Possible Redemption TemporaryEquitySubjectToPossibleRedemption	1337763	shares
CY2023Q2	KACL	Temporary Equity Subject To Possible Redemption TemporaryEquitySubjectToPossibleRedemption	2089816	shares
CY2024Q1	KACL	Temporary Equity Carrying Amount TemporaryEquityCarryingAmount	15792577	usd
CY2023Q2	KACL	Temporary Equity Carrying Amount TemporaryEquityCarryingAmount	22802239	usd
CY2023	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	5710184	shares
	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	752053	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zMZSgrGb7Scd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zixJ2INaYepc">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20240331_zPhH0U3Mgrlb" title="Cah FDIC insured amount">250,000</span>. The Company has not experienced losses on this account. The Company has not experienced any losses on the Trust Account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q1	KACL	Management Fees Expense ManagementFeesExpense	14969	usd
	KACL	Management Fees Expense ManagementFeesExpense	30000	usd
	KACL	Management Fees Expense ManagementFeesExpense	44969	usd
CY2024Q1	us-gaap	Management Fee Expense ManagementFeeExpense	15000	usd
	us-gaap	Management Fee Expense ManagementFeeExpense	15000	usd
CY2024Q1	us-gaap	Management Fee Payable ManagementFeePayable	15000	usd
CY2024Q1	KACL	Working Capital Loans Sponsor WorkingCapitalLoansSponsor	881066	usd
CY2023Q2	KACL	Working Capital Loans Sponsor WorkingCapitalLoansSponsor	420000	usd
CY2024Q1	KACL	Extension Loans ExtensionLoans	1640000	usd
CY2023Q2	KACL	Extension Loans ExtensionLoans	840000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1125000	shares
	KACL	Deferred Purchase Fee DeferredPurchaseFee	100	usd
	KACL	Deferred Underwriting Fee DeferredUnderwritingFee	105000	usd
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	39000	shares
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	341230	usd
CY2022Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	2000000	usd
CY2022Q4	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	2730000	usd
CY2022Q4	us-gaap	Share Price SharePrice	10.00
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2346143	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2346143	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2346143	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2346143	shares
CY2024Q1	KACL	Shares Subject To Mandatory Redemption Settlement Terms Shares SharesSubjectToMandatoryRedemptionSettlementTermsShares	1337763	shares
CY2023Q2	KACL	Shares Subject To Mandatory Redemption Settlement Terms Shares SharesSubjectToMandatoryRedemptionSettlementTermsShares	2089816	shares
CY2023	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	5710184	shares
CY2023	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	58312401	usd
CY2023Q4	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	752053	shares
CY2023Q4	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	8621702	usd
	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Description SharesSubjectToMandatoryRedemptionSettlementTermsDescription	if, and only if, the reported last sale price of the ordinary shares equals or exceeds $16.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30-trading day period commencing at any time after the warrants become exercisable and ending on the third business day prior to the notice of redemption to warrant holders

Files In Submission

Name	View Source	Status
0001493152-24-020672-index-headers.html	Edgar Link	pending
0001493152-24-020672-index.html	Edgar Link	pending
0001493152-24-020672.txt	Edgar Link	pending
0001493152-24-020672-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
kacl-20240331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
kacl-20240331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
kacl-20240331_cal.xml	Edgar Link	unprocessable
kacl-20240331_def.xml	Edgar Link	unprocessable
kacl-20240331_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KACLF
Kairous Acquisition Corp. Ltd Stock $kaclf

2024 Q2 Form 10-Q Financial Statement

#000149315224020672 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KACLF Kairous Acquisition Corp. Ltd Stock $kaclf

2024 Q2 Form 10-Q Financial Statement

#000149315224020672 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KACLF
Kairous Acquisition Corp. Ltd Stock $kaclf